

October 14, 2020



## **MariMed's CEO to Participate in Fireside Chat at the Benzinga Virtual Cannabis Capital Conference on October 15th**

NORWOOD, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- [MariMed Inc.](#) (MRMD:OTCQX) (the "Company" or MariMed), a leading multi-state cannabis and hemp operator focused on health and wellness, today announced that the Company's Chief Executive Officer Bob Fireman will speak at the Benzinga Virtual Cannabis Capital Conference on Thursday, October 15th.

Mr. Fireman will participate in a fireside chat with Managing Director of Benzinga Cannabis Javier Hasse at 12:30 pm ET. Topics will include MariMed's revenue spike in the robust Massachusetts and Illinois cannabis markets and the positive effect it has had on its consolidation strategy. The Company's management will also conduct one on one meetings with institutional investors in the cannabis space, providing additional color on the Company's growth strategy in an evolving regulatory and retail market.

Interested investors can find more information and register for the virtual event at [this link](#).

To be added to the email distribution list, please email [MRMD@kcsa.com](mailto:MRMD@kcsa.com) with "MRMD" in the subject.

### **About MariMed:**

MariMed Inc., a multi-state cannabis operator, is dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products. The Company develops, owns and manages seed-to-sale, state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units.

The Company is at the forefront of science and innovation through research developed by its lab technicians and medical advisors resulting in industry-leading products and brands, including "Betty's Eddies™", "Nature's Heritage™", "Bourne Baking Co.", and "Kalm Fusion™". These precision dosed products are focused on specific symptoms and conditions and are licensed and distributed across the country.

For additional information, visit [marimedinc.com](http://marimedinc.com).

### **Important Caution Regarding Forward-Looking Statements:**

This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.'s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events, including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement and changes in the economic environment. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned," "estimated," "preparing," "potential," "expected," "looks" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

All trademarks and service marks are the property of their respective owners.

**Company Contact**

Jon Levine, CFO  
MariMed Inc.  
Tel (781) 559-8713

**Media Contact**

Abigail Diehl  
MariMed Inc.  
adiehl@marimedinc.com

**Investors**

KCSA Strategic Communications  
Scott Eckstein / Elizabeth Barker  
MRMD@kcsa.com



Source: MariMed Inc.